Malinda Wu, MD, MSCR
Pediatric Endocrinology
Highlights
Age Groups Seen
- Infant 0-2
- Child 3-12
- Adolescent 13-17
Languages
- English
In-Network Plans
View All Accepted Plans (12)Gender
FemaleJohns Hopkins Affiliations:
- Johns Hopkins School of Medicine Faculty
About Malinda Wu
Primary Academic Title
Assistant Professor of Pediatrics
Johns Hopkins Physician
Background
Dr. Malinda Wu is a pediatric endocrinologist seeing patients at the Johns Hopkins Children’s Center in Baltimore, Maryland. She specializes in a wide range of pediatric endocrine conditions including metabolic bone disease, pediatric osteoporosis and cystic fibrosis endocrinopathies.
Dr. Wu received her M.D. from Jefferson Medical College, Thomas Jefferson University. She completed pediatrics residency at Penn State Hershey Medical Center and her pediatric endocrine fellowship at Emory University School of Medicine. She received her Master of Science in Clinical Research from Emory University (2021). Dr. Wu has been a faculty member at Johns Hopkins since 2021.
Dr. Wu’s research interests are in metabolic bone disease and the health of women with cystic fibrosis. Dr. Wu’s current research is focused on women with cystic fibrosis and how estrogen supplementation may impact their health. She has received grant funding from the Cystic Fibrosis Foundation.
Find a Clinical Trial
View all trials by this principal investigator.
Research Interests
COVID-19 and access to care, Cystic fibrosis, estrogen supplementation and bone health, metabolic bone disease, pediatric osteoporosis, quality of life
Research Summary
Dr. Wu’s current research is focused on women with cystic fibrosis (CF) and how estrogen supplementation may impact their health.
Her results show that women with CF who were taking supplemental estrogen such as combined oral contraceptives have higher quality of life scores than women with CF not taking supplemental estrogen. In a single-center cross-sectional study, women with CF taking estrogen supplementation (ethinyl estradiol) had lower bone mineral density than women with CF not taking ethinyl estradiol. Dr. Wu questions whether oral ethinyl estradiol, which is the common estrogen used in oral contraceptive pills, is adequate to protect bone health and if there needs to be a higher dose of estrogen or a different route like a patch to make a difference.
Dr. Wu is also doing research that looks at the impact of COVID-19 pandemic on the quality of life of patients with osteogenesis imperfecta and their access to care. Many individuals had delays in accessing medical providers and services relating to their care. The preliminary findings were presented at the virtual International Conference on Children’s Bone Health forum.
PubMed - Publications
Honors
- Harry Shwachman Clinical Investigator Award, Cystic Fibrosis Foundation
- Henry Christian Award, American Federation for Medical Research
Memberships
- Pediatric Endocrine Society
- Endocrine Society
- American Society for Bone and Mineral Research
Locations
- Rubenstein Child Health Building
- 200 North Wolfe Street, Building 1, Baltimore, MD 21287
- Get Directions
- phone: 443-997-5437
- fax: 410-500-4276
Expertise
Education
- Graduate School: Emory University School of Medicine, Clinical Research, MSCR, 2021
- Fellowship: Emory University School of Medicine, Pediatric Endocrinology, 2020
- Residency: Penn State Hershey Medical Center, Pediatrics, 2017
- Medical Education: Sidney Kimmel Medical College, MD, 2014
Board Certifications
- Pediatric Endocrinology: American Board of Pediatrics, 2021
- Pediatrics: American Board of Pediatrics, 2017
Insurance
- Aetna
- CareFirst
- Cigna
- First Health
- Geisinger Health Plan
- HealthSmart/Accel
- Johns Hopkins Health Plans
- MultiPlan
- Pennsylvania's Preferred Health Networks (PPHN)
- Point Comfort Underwriters
- Private Healthcare Systems (PHCS)
- Veteran Affairs Community Care Network (Optum-VACCN)